The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)

ConditionsKidney Failure, Acute Myopathy; Drugs Heart Arrhythmia Succinylcholine Sensitivity Muscle Relaxation General Anesthetic Drug Adverse Reaction Projection

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-90

Sponsor4th Military Clinical Hospital with Polyclinic, Poland

About this trial

The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.

Eligibility criteria

Qualifiers

Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation

Disqualifiers

Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.

Trial design

Treatments tested in this trial

Propofol
Rocuronium

Treatment groups

32 Participants

are divided into 2 treatment groups

Locations

4th Military Clinical Hospital with Polyclinic50-981, WroclawLower Silesian Voivodeship, Poland

Sponsors and collaborators

4th Military Clinical Hospital with Polyclinic, Poland

Lead sponsor

Source ClinicalTrials.gov